Is Rutoside compatible with breastfeeding? Do we have alternatives for Rutoside?

Rutoside

January 7, 2018 (Very Low Risk)

Bioflavonoid type substances.

Flavonoids are phenolic compounds naturally occurring that are abundantly present in plants and seaweed.

We take it from fruits, vegetables, tea and red wine (as a few examples)

Most important types are: anthocyanins, chalcons, flavonols, flavones, flavonoids and tannins. No risk for toxic nor side-effects in humans have been found.

They appear naturally in the breast milk in amounts related to mother's diet.

Attributed anti-oxidant activity and other properties that have not been fully shown yet (Martinez 2016, Morling 2015, Cohen 2012), as amelioration of capillary vessel function which is a reason to be used for treatment of venous insufficiency (varicose veins), hemorrhoids and prevention of arteriosclerosis.

Alternatives

We do not have alternatives for Rutoside since it is relatively safe.

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Synonyms

  • Rutin
  • Sophorin

Writings

  • ερυθρίνη (Greek)
  • روتوسيد (Arabic)
  • Рутозид (Cyrillic)
  • 芦丁 (Chinese)
  • ルチン; ルトシド (Japanese)
  • Rutoside (French)
  • C27H30O16,3H2O (Molecular formula)
  • 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside (Chemical name)

Drug trade names

References

  1. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, Capellà D, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016Abstract
  2. Morling JR, Yeoh SE, Kolbach DN. Rutosides for treatment of post-thrombotic syndrome. Cochrane Database Syst Rev. 2015Abstract
  3. Cohen JM, Akl EA, Kahn SR. Pharmacologic and compression therapies for postthrombotic syndrome: a systematic review of randomized controlled trials. Chest. 2012Abstract
  4. AESAN. Informe del Comité Científico de la Agencia Española de Seguridad Alimentaria y Nutrición (AESAN) sobre condiciones de uso de determinadas sustancias distintas de vitaminas, minerales y plantas para ser empleadas en complementos alimenticios - 1. Revista del comité científico nº 17. 2012 Full text (in our servers)
  5. Jaganath IB, Mullen W, Edwards CA, Crozier A. The relative contribution of the small and large intestine to the absorption and metabolism of rutin in man. Free Radic Res. 2006Abstract
  6. Schwedhelm E, Maas R, Troost R, Böger RH. Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. Clin Pharmacokinet. 2003Abstract
  7. Kienzler JL, Sallin D, Schifflers MH, Ghika A. Pharmacokinetics of mono-3'- and mono-4'-0-(beta-hydroxyethyl)-rutoside derivatives, after single doses of Venoruton powder in healthy volunteers. Eur J Clin Pharmacol. 2002Abstract
  8. Erlund I, Alfthan G, Mäenpää J, Aro A. Tea and coronary heart disease: the flavonoid quercetin is more bioavailable from rutin in women than in men. Arch Intern Med. 2001Abstract